摘要
目的 探讨人参皂苷对系统性红斑狼疮患者血清IL-17和IL-23的影响.方法 将86例系统性红斑狼疮患者按照数字表法随机分为两组,对照组43例,观察组43例,对照组采用泼尼松治疗,观察组在对照组治疗的基础上加用人参皂苷,两组均治疗3个月.评价系统性红斑狼疮活动性指数（SLEDAI）、血清补体3（C3）、IL-17和IL-23.结果 治疗后,两组SLEDAI均有明显降低,观察组较对照组降低更明显（t=2.73,P＜0.05）;血清C3均有明显升高,观察组较对照组升高更明显（t=3.04,P＜0.05）;血清IL-17和IL-23均有明显降低,观察组较对照组降低更明显（t=2.13、3.06,均P＜0.05）.不良反应发生率对照组25.6％,观察组7.0％,两组差异有统计学意义（x2=4.89,P＜0.05）.结论 人参皂苷可以明显降低系统性红斑狼疮患者血清IL-17和IL-23的表达.
Objective To study the effectiveness of Ginsenoside on serum IL-17 and IL-23 in patients with systemic lupus erythematosus.Methods According to the digital table,86 patients with systemic lupus erythematosus （SLE） were randomly divided into two groups,the control group （n =43 cases） and the observation group （n =43 cases）.The patients in the control group were treated through prednisone,while the patients in the observation group were treated through prednisone plus ginsenoside.They were all treated for three months,systemic lupus erythematosus activity index（SLEDAI）,serum complement 3 （C3）,IL-17 and IL-23 were evaluated.Results SLEDAI after treatment were significantly decreased,compared with the control group,the observation group decreased more significantly （t =2.73,P 〈 0.05）.Mtertreatment,serum C3 were significantly elevated,compared with thecontrol group,the observation group increased more significantly（t =3.04,P 〈0.05）.After treatment,serum IL-17 and IL-23 were significantly reduced,and after treatment compared with the control group,the observation group decreased more significantly （t =2.13,3.06,all P 〈 0.05）.The rates of adverse reactions were 25.6% in the control group and 7.0% in the observation group.There was a statistically significance between two groups （x2 =4.89,P 〈 0.05）.Conclusion Ginsenoside can decrease serum IL-17 and IL-23 in patients with systemic lupus erythematosus.
出处
《中国基层医药》
CAS
2014年第8期1147-1149,共3页
Chinese Journal of Primary Medicine and Pharmacy
